HIGHLIGHTS
- who: Cilgavimab/Tixagevimab et al. from the Center of Virology, Medical University of Vienna, Vienna, Austria have published the article: SARS-CoV-2 Omicron BA.1/ BA.2 Neutralization up to 8 Weeks After PrEP With Sotrovimab or Cilgavimab/Tixagevimab, in the Journal: (JOURNAL)
- how: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
SUMMARY
Transplant International | Published by Frontiers December 2022 | Volume 35 | Article 10906 Sotrovimab or Cilgavimab/Tixagevimab Against SARS-CoV . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.